Anthony Clare

Partner

Anthony advises on a wide range of corporate matters including M&A (public and private), joint ventures and equity capital markets. He has acted on over 20 IPOs in the London market, and a number of high profile cross-border public M&A mandates.

Anthony is named as a 'star' in the corporate section of the 2015 edition of LMG Life Sciences and is listed in the Top 50 European M&A lawyers 2014 by Global M&A Network (EMEA). He has been ranked in Chambers for the last three years as a leading individual for M&A: High End Capability.

Anthony has served for over nine years on the board, and as Vice Chairman, of The Babraham Institute, Cambridge, a leading European bioscience research institute.

Anthony’s life sciences experience includes advising:

e-therapeutics on its £22.5 million fundraise. Based in Oxford, UK, e-therapeutics aims to transform the drug discovery process by leveraging its computational power and biological expertise to accelerate the path to identifying and developing effective therapies.
Acacia Pharma Group plc, a pharmaceutical company specialising in the development of drugs for cancer and post-operative supportive care, on its Euronext Brussels IPO, and prior to that on its Series A, B and C investment rounds to fund development of its two lead products.
Silence Therapeutics plc on its acquisition by way of reverse takeover of Palo Alto-based Intradigm Corporation, and the associated £15 million equity fundraising through a placing, to create a leading company in the field of RNA interference (RNAi).
Ark Therapeutics Group plc on its acquisition of Helsinki-based Lymphatix Oy giving Ark Therapeutics royalty-free exploitation rights to the vascular endothelial growth factor genes known as VEGF-D and VEGF-C, complementing its existing portfolio of VEGF-based programmes.
UCB Biopharma on various strategic investments alongside financial investors in various early stage portfolio companies, in both the US and throughout Europe.
Ark Therapeutics Group plc in relation to two placings and open offers of shares raising, respectively, £37.4 million and £27.1 million, and on its original flotation on the London Stock Exchange.
NeuTec Pharma Plc on its £305.1 million recommended cash takeover by Novartis.
SR Pharma plc on its £8.3 million placing of new shares with institutional investors and the £1.7 million equity investment in the company by Nasdaq-listed biotech company Introgen Therapeutics Inc., following its acquisition of Atugen AG.
Arakis Limited on a £29 million private funding round.
Arakis Limited and its shareholders on the acquisition of Arakis by Sosei Co. Ltd., a leading Japanese biopharmaceutical company, creating a global biopharmaceutical company with an implied value of £278 million.
Quadrant Technologies Limited on its £46.7 million sale to ML Laboratories plc.
Cambridge Antibody Technology plc in connection with a £75 million subscription by AstraZeneca of a 19.9 per cent equity stake.
Inion Oy, Quadrant Healthcare and Ark Therapeutics on their London Stock Exchange listings.
Quadrant Technologies Limited on its acquisition from Elan Corporation, plc of the UK-based drug delivery business Elan Drug Delivery Limited (EDD-UK).
NM Rothschild, JP Morgan Cazenove and Peel Hunt as the sponsor and joint bookrunners on a Class 2 acquisition and related placing by Vectura plc.